Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases
March 03 2022 - 8:00AM
Business Wire
Medical experts discuss the potential use of
prescription digital therapeutics (PDTs) delivering cognitive
behavior therapy to address behavioral root causes of disease
The role of data generated through randomized,
controlled trials and real-world evidence studies on payer coverage
and reimbursement is examined
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX),
a prescription digital therapeutics company developing cognitive
behavioral therapy to address the root causes of cardiometabolic
diseases, in collaboration with MedEd On The Go, today announced
the availability of an on-demand, educational symposium entitled,
“Next Generation Therapeutics for Cardiometabolic Diseases: Using
Software Instead of Drugs.”
The on-demand educational symposium is moderated by Christopher
Cannon, MD, professor at Harvard Medical School and cardiologist at
Brigham and Women’s Hospital, and it includes panelists Marc
Bonaca, MD, executive director of Colorado Prevention Center
Clinical Research and associate professor at University of
Colorado; Maria Lopes, MD, chief medical officer at AMC Health; and
Benjamin Scirica, MD, associate professor at Harvard Medical School
and cardiologist at Brigham and Women’s Hospital.
“Nearly half a trillion dollars are spent each year dealing with
the symptoms of type 2 diabetes, heart disease and other
cardiometabolic conditions, while little is done to address the
behaviors that are root causes,” said Kevin Appelbaum, CEO of
Better Therapeutics. “PDTs that use software instead of drugs to
deliver a new kind of cognitive behavior therapy shows promise as a
treatment alternative that can address the root causes of disease,
improving patient health while reducing healthcare costs and the
ongoing need for medications.”
The symposium highlights the scope of the problem in type 2
diabetes, application of cognitive behavioral therapy in the form
of a PDT, the evidence standards for payer evaluation and coverage,
and how Better Therapeutics’ pivotal trial and real-world evidence
program will meet providers and payer evidence needs. The
educational symposium can be accessed in its entirety via:
www.mededonthego.com/refer/name/BetterTxPR852
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220303005323/en/
Better Therapeutics Media Contact Cassidy McClain
Cassidy.McClain@canalecomm.com +1 619 849 6009
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024